Lisa Strug

Title: Innovations by Lisa Strug in Cystic Fibrosis Research

Introduction

Lisa Strug is a prominent inventor based in Toronto, Canada. She has made significant contributions to the field of cystic fibrosis research, particularly in the development of genetic modifiers that enhance the efficacy of CFTR-directed therapies. Her work has the potential to improve treatment outcomes for patients suffering from this genetic disorder.

Latest Patents

Lisa Strug holds a patent titled "Modifiers of CFTR-directed therapy." This patent describes a genetic modifier of cystic fibrosis (CF) that may serve as a predictor of the efficacy of CFTR-directed therapy. The patent highlights specific SNPs, such as rs7512462 and rs2869027, in non-coding regions of SLC26A9 that correlate with CF lung disease severity in patients with CFTR mutations. The findings indicate that patient response to Ivacaftor correlates with SLC26A9 genotype, suggesting that SLC26A9 activity can predict treatment efficacy for CFTR-directed therapeutics.

Career Highlights

Throughout her career, Lisa Strug has been associated with esteemed institutions such as the University of Toronto and The Hospital for Sick Children. Her research has focused on understanding the genetic factors that influence cystic fibrosis and developing innovative therapies to improve patient care.

Collaborations

Lisa has collaborated with notable researchers, including Lei Sun and Johanna Rommens. These collaborations have furthered the understanding of cystic fibrosis and contributed to advancements in treatment strategies.

Conclusion

Lisa Strug's innovative work in cystic fibrosis research exemplifies the impact of genetic modifiers on treatment efficacy. Her contributions are paving the way for more effective therapies and improved patient outcomes in the field of cystic fibrosis.